Details Basic Details Status Ongoing Last Updated Thursday, May 26, 2022 Original Posting Date Friday, May 25, 2018 Health Outcome(s) lymphoma Purpose Drug and Outcome Analysis Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR Yes Result(s) (1) Lymphoma Risk following Guselkumab, Risankizumab, or Tildrakizumab Use: A Descriptive Analysis Regulatory Link(s) (1) Approval Letter